Cite
Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)
MLA
Grimaldi-Bensouda, Lamiae, et al. “Does Long-Acting Injectable Risperidone Make a Difference to the Real-Life Treatment of Schizophrenia? Results of the Cohort for the General Study of Schizophrenia (CGS).” Schizophrenia Research, vol. 134, no. 2/3, Feb. 2012, pp. 187–94. EBSCOhost, https://doi.org/10.1016/j.schres.2011.10.022.
APA
Grimaldi-Bensouda, L., Rouillon, F., Astruc, B., Rossignol, M., Benichou, J., Falissard, B., Limosin, F., Beaufils, B., Vaiva, G., Verdoux, H., Moride, Y., Fabre, A., Thibaut, F., & Abenhaim, L. (2012). Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophrenia Research, 134(2/3), 187–194. https://doi.org/10.1016/j.schres.2011.10.022
Chicago
Grimaldi-Bensouda, Lamiae, Frederic Rouillon, Bernard Astruc, Michel Rossignol, Jacques Benichou, Bruno Falissard, Frederic Limosin, et al. 2012. “Does Long-Acting Injectable Risperidone Make a Difference to the Real-Life Treatment of Schizophrenia? Results of the Cohort for the General Study of Schizophrenia (CGS).” Schizophrenia Research 134 (2/3): 187–94. doi:10.1016/j.schres.2011.10.022.